In this video, Dr. Sarah Telaney, a breast medical oncologist at Dana-Farber Cancer Institute, shares key takeaways from ESMO 2024, highlighting three impactful studies in breast oncology. She discusses the promising outcomes of preoperative pembrolizumab for early-stage triple-negative breast cancer, the significant efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic HER2-positive disease and brain metastases, and the recently FDA-approved ribociclib for early-stage hormone receptor-positive breast cancer. Dr. Telaney emphasizes the exciting pace of drug development and its potential to improve patient care.